<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

1 min read

SmartTRAK Cited in Smith & Nephew Osiris Acquisition Press Release

4/8/19 10:13 AM

S&N OrisirsSmartTRAK was cited as a source in a press release from Smith & Nephew entitled "Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc."

S&N, in their presentation, announced that it has agreed to acquire Osiris Therapeutics, a fast growing company delivering regenerative medicine products, including skin, bone graft and articular cartilage substitutes, for $19.00 per share in cash, representing a total equity value of approximately $660 million, and referenced SmartTRAK Market Research as their source for Grafix and Stravix participation numbers  in the US skin substitute market, reporting that they are currently worth $900MM per annum and growing 7% annually.

SanN_In_the_news_slide_mar-14-2019

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic & wound care companies.  If you would like a demo of what SmartTRAK has to offer and how we can help increase proficiency, improve productivity and reduce costs for your company, just click the button below.

Request a Demo of the SmartTRAK  Business Intelligence Portal!

 

Topics: Wound Care

Susan Paquette
Written by Susan Paquette

Susan Paquette, MS, MBA | Vice President and General Manager, Wound. 25+ years' experience in new business development, R&D, international and marketing. Director, New Business Development & Commercialization, 3M Health Care; Technical Director, 3M Medical.

    Recent Articles